Epithelial Ovarian Cancer and Low Malignant Potential (LMP) Tumors Associated With a Lower Incidence of Second Primary Breast Cancer

Hunter, Mark; Ziogas, A.; Flores, Francisca; Brewster, Wendy R.

doi:10.1097/01.coc.0000231364.89294.13

Cited by 6 publications

(12 citation statements)

References 29 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 – 9 , 11 – 21 Most of these studies demonstrated an increased risk of SPM, 5 – 8 , 12 , 14 , 15 , 17 , 18 , 20 but others did not. 9 , 11 , 13 Bergfeldt et al 9 proposed that findings of increased occurrence of secondary primary cancer in patients with ovarian cancer have been biased by misclassification. A study conducted in the UK confirmed the high incidence of synchronous cancer in patients with ovarian cancer, which may also bias estimates of SPM incidence.…”

Section: Discussionmentioning

confidence: 99%

“… 12 Several studies have described an increased risk of secondary breast cancer after ovarian cancer, with a focus on invasive forms. 11 , 13 , 15 Several possible explanations may be offered for the increased risk of SPM after ovarian cancer. First, an inherent or acquired defect of tumor suppressor genes or DNA repair genes may induce such cancers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Hung

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To evaluate the incidence of secondary primary malignancy (SPM) in patients with ovarian cancer using a nationwide retrospective population-based dataset.Patients newly diagnosed with ovarian cancer between 1997 and 2010 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated and compared with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models. Effects of surgery, chemotherapy, and radiotherapy after ovarian cancer diagnosis were regarded as time-dependent variables to prevent immortal time bias.During the 14-year study period (follow-up of 56,214 person-years), 707 cancers developed in 12,127 patients with ovarian cancer. The SIR for all cancers was 2.78 (95% confidence interval 2.58–3.00). SIRs for follow-up periods of >5, 1–5, and <1 year were 1.87, 2.04, and 6.40, respectively. After the exclusion of SPM occurring within 1 year of ovarian cancer diagnosis, SIRs were significantly higher for cancers of the colon, rectum, and anus (2.14); lung and mediastinum (1.58); breast (1.68); cervix (1.65); uterus (7.96); bladder (3.17), and thyroid (2.23); as well as for leukemia (3.98) and others (3.83). Multivariate analysis showed that age ≥ 50 years was a significant SPM risk factor (hazard ratio [HR] 1.60). Different treatments for ovarian cancer, including radiotherapy (HR 2.07) and chemotherapy (HR 1.27), had different impacts on SPM risk.Patients with ovarian cancer are at increased risk of SPM development. Age ≥ 50 years, radiotherapy, and chemotherapy are independent risk factors. Close surveillance of patients at high risk should be considered for the early detection of SPM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Hung

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

show abstract

“…Several studies have reported significantly higher relative risks of second primary cancers subsequent to ovarian cancer, such as colorectal cancer, 8‐12 breast cancer, 8,9,11,12 bladder cancer, 8‐12 and leukemia, 8‐10,12,13 probably due to common etiology, hereditary factors and chemotherapy‐induced secondary malignancies. Few studies, however, have examined relative risks of cancer following BOTs 14‐17 . One study found no increased relative risk of cancers, 17 whereas two studies reported significantly elevated risks of ovarian 16 and colorectal cancer 15 .…”

Section: Introductionmentioning

confidence: 99%

Risk of nonovarian cancer in a nationwide‐based study of nearly 5000 women with borderline ovarian tumors in Denmark

Hannibal

Baandrup

Hertzum‐Larsen

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Evidence regarding cancer risk after borderline ovarian tumors (BOTs) is limited. We conducted a nationwide cohort study examining the incidence of nonovarian cancers in women with serous or mucinous BOTs compared with the general female population with up to 41 years of follow‐up. Through the nationwide Pathology Registry, we identified nearly 5000 women with BOTs (2506 serous and 2493 mucinous) in Denmark, 1978 to 2018. We computed standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) as relative risk estimates of specific nonovarian cancers. Compared with general female population rates, women with serous BOTs had increased rates of particularly malignant melanoma (SIR = 1.9; 95% CI: 1.3‐2.6), thyroid cancer (SIR = 3.0; 95% CI: 1.4‐5.4) and myeloid leukemia (SIR = 3.2; 95% CI: 1.5‐5.8), and women with mucinous BOTs had elevated rates of lung cancer (SIR = 1.7; 95% CI: 1.3‐2.1), pancreatic cancer (SIR = 1.9; 95% CI: 1.2‐2.9) and myeloid leukemia (SIR = 2.3; 95% CI: 0.9‐4.7). We found no convincing association with neither breast nor colorectal cancer in women with BOTs. This is the first large nationwide study showing that women with specific types of BOTs have increased risks of several nonovarian cancers, likely due to some shared risk factors or genetic characteristics.

show abstract

“…Furthermore, for the 20% of OECs that express little or no CA125, a single marker is not sufficient. In particular, HE4 levels are elevated in more than 50% of tumours that do not express CA125 [42]. Therefore, the addition of HE4 to CA125 allows detecting malignancies in patients with tumours that do not express CA125 and will be missed by algorithms using CA125 alone.…”

Section: Roma Algorithmmentioning

confidence: 99%

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Elorriaga

Neyro

Mieza

et al. 2021

JPM

View full text Add to dashboard Cite

Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosis, response to treatments and identification of recurrence in patients with ovarian masses. Methodology: Systematic search of publications in English in the Medline-PubMed database with the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications were selected to write this article to determine the usefulness of tumour markers and algorithms in ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4 individually or as a basis for decision-making algorithms has low specificity; however, there is little evidence that confirms their usefulness as markers in ovarian cancer screening.

show abstract

Epithelial Ovarian Cancer and Low Malignant Potential (LMP) Tumors Associated With a Lower Incidence of Second Primary Breast Cancer

Abstract: Patients with a history of having either an LMP tumor or an epithelial ovarian cancer have a less than expected risk of subsequent breast cancer. Patients with LMP tumors are at lower risk than patients with a history of ovarian cancer for the development of these second malignancies.

Cited by 6 publications

References 29 publications

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

Risk of nonovarian cancer in a nationwide‐based study of nearly 5000 women with borderline ovarian tumors in Denmark

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Contact Info

Product

Resources

About